Loading stock data…
Harmony Biosciences Holdings (HRMY)
$35.34-0.13 (-0.37%)
Market ClosedLast close Jun 29
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Harmony Biosciences Holdings, Inc. in the Healthcare sector is trading at $35.34 with a market capitalization of $2.0B. Wall Street consensus targets $44.36 (11 analysts), implying a +25.5% move over the next 12 months. The stock is currently 14% below its 52-week high of $40.87, remaining 9.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +25.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $215.39M↓ | $243.78M↑ | $239.46M↑ | $200.49M↑ | $184.73M |
| Gross Profit | $170.88M↓ | $175.23M↓ | $179.81M↑ | $162.34M↑ | $152.74M |
| Operating Income | $37.29M↓ | $38.56M↓ | $65.49M↑ | $48.18M↓ | $56.24M |
| Net Income | $32.49M↑ | $22.49M↓ | $50.87M↑ | $39.78M↓ | $45.56M |
Peer Comparison
JNJUNHPFE
Fundamentals
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
16.00%
Volume
Today's trading volume
791,751
Recent News
Harmony Biosciences (HRMY) Stock Valuation After New Pitolisant Data And Reaffirmed Guidance
Harmony Biosciences Holdings (HRMY) is back in focus after announcing six Pitolisant related abstracts accepted for presentation at the SLEEP 2026 conference, alongside reaffirmed guidance and updated timelines for key pipeline milestones. See our latest analysis for Harmony Biosciences Holdings. Despite a small pullback in the latest session, Harmony Biosciences’ recent news on Pitolisant abstracts and reaffirmed guidance comes alongside a 30 day share price return of 16.75% and a 1 year...
Is Harmony Biosciences Holdings, Inc. (HRMY) A Good Stock To Buy Now?
Is HRMY a good stock to buy? We came across a bullish thesis on Harmony Biosciences Holdings, Inc. on r/StockPickNews by EaseQuiet529. In this article, we will summarize the bulls’ thesis on HRMY. Harmony Biosciences Holdings, Inc.’s share was trading at $34.10 as of June 9th. HRMY’s trailing and forward P/E were 13.75 and 10.81 respectively according […]
Looking Back at Stock Picks Hyatt Hotels, Sensient Technologies, Harmony Biosciences. What the Charts Say.
Reviewing past stock picks is an essential part of the investment process. Harmony Biosciences which Todd Chanko reviewed in March. Watch Doug discuss recent stock picks, provide his input on the current market environment—and take your questions.
Harmony Biosciences Holdings (HRMY): One of the Best Stocks to Buy According to AI
We just covered the 10 Best Stocks to Buy Right Now According to AI and Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) ranks 10th on this list. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company focused on developing therapies for patients suffering from rare neurological diseases. The flagship commercial product is WAKIX (pitolisant), a first-in-class […]
A beaten-down biotech just lost a meaningful backer — should you care?
Harmony Biosciences develops therapies for rare neurological disorders, with WAKIX addressing excessive sleepiness in narcolepsy patients.